ATE71092T1 - Hydroxybutenolid-derivate, ihre herstellung und ihre verwendung. - Google Patents

Hydroxybutenolid-derivate, ihre herstellung und ihre verwendung.

Info

Publication number
ATE71092T1
ATE71092T1 AT87112439T AT87112439T ATE71092T1 AT E71092 T1 ATE71092 T1 AT E71092T1 AT 87112439 T AT87112439 T AT 87112439T AT 87112439 T AT87112439 T AT 87112439T AT E71092 T1 ATE71092 T1 AT E71092T1
Authority
AT
Austria
Prior art keywords
compound
hydroxybutenolide
derivatives
preparation
hydrocarbon residue
Prior art date
Application number
AT87112439T
Other languages
English (en)
Inventor
Shinji Terao
Minoru Hirata
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Application granted granted Critical
Publication of ATE71092T1 publication Critical patent/ATE71092T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/62—Three oxygen atoms, e.g. ascorbic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/60—Two oxygen atoms, e.g. succinic anhydride

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Furan Compounds (AREA)
AT87112439T 1986-08-29 1987-08-27 Hydroxybutenolid-derivate, ihre herstellung und ihre verwendung. ATE71092T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP20483286 1986-08-29
EP19870112439 EP0259707B1 (de) 1986-08-29 1987-08-27 Hydroxybutenolid-Derivate, ihre Herstellung und ihre Verwendung

Publications (1)

Publication Number Publication Date
ATE71092T1 true ATE71092T1 (de) 1992-01-15

Family

ID=16497122

Family Applications (1)

Application Number Title Priority Date Filing Date
AT87112439T ATE71092T1 (de) 1986-08-29 1987-08-27 Hydroxybutenolid-derivate, ihre herstellung und ihre verwendung.

Country Status (6)

Country Link
US (1) US4939274A (de)
EP (1) EP0259707B1 (de)
JP (1) JP2515556B2 (de)
AT (1) ATE71092T1 (de)
CA (1) CA1328109C (de)
DE (1) DE3775666D1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989009769A1 (fr) * 1988-04-14 1989-10-19 Yamanouchi Pharmaceutical Co., Ltd. Substance dite q-2819 et procede de preparation d'une telle substance
JP2830268B2 (ja) * 1989-01-21 1998-12-02 武田薬品工業株式会社 アスコルビン酸誘導体の製造法
US5095126A (en) * 1990-01-12 1992-03-10 Ohio State University Research Foundation Efficient synthesis for optically pure stereogenically labile 4-substituted-2-hydroxytetronic acids
EP0446539A1 (de) * 1990-03-16 1991-09-18 Merrell Dow Pharmaceuticals Inc. Ascorbinsäure-Derivate
US5270336A (en) * 1990-03-16 1993-12-14 Merrell Dow Pharmaceuticals Inc. Ascorbic acid derivatives
US5071872A (en) * 1990-08-14 1991-12-10 The Ohio State University Research Foundation Method for improving interleukin-2 activity using aci-reductone compounds
JPH0656669A (ja) * 1992-06-11 1994-03-01 Asahi Breweries Ltd 活性酸素消去作用を持つプテリン誘導体製剤
EP0720607A1 (de) * 1993-09-17 1996-07-10 PHARMACIA & UPJOHN COMPANY Substituierte tetronsäuren zur behandlung von hiv und anderen retroviren
JPH07188024A (ja) * 1993-12-27 1995-07-25 Asahi Breweries Ltd 脳循環障害治療剤
SI0817786T1 (en) * 1995-03-20 2003-08-31 Pharmacia & Upjohn Company Substituted tetronic acids useful for treating hiv and other retroviruses

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1404689A (fr) * 1963-06-05 1965-07-02 Olin Mathieson Procédé de préparation de nouvelles lactones
DE1920176A1 (de) * 1969-04-21 1970-10-22 Thomae Gmbh Dr K Neues Verfahren zur Herstellung von Hydroxycrotonsaeurelaktonen
US3981857A (en) * 1973-03-19 1976-09-21 Konishiroku Photo Industry Co., Ltd. Gelatin hardening process
US4164585A (en) * 1976-07-01 1979-08-14 Cardioquest Corporation Anti-thrombotic compound and method of making and using the same for pharmaceutical purposes
JPS57102753A (en) * 1980-12-17 1982-06-25 Nikko Kikai Kk Shaping method for metal bonding grindstone
IL67646A0 (en) * 1982-01-15 1983-05-15 Lilly Co Eli Ascorbic acid ethers and related compounds
EP0086324B1 (de) * 1982-02-12 1988-09-21 F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft Verfahren zur Herstellung von Ascorbinsäure
DE3476387D1 (en) * 1983-08-05 1989-03-02 Hoffmann La Roche Process for the preparation of carbohydrates
JPS60130582A (ja) * 1983-12-19 1985-07-12 Takeda Chem Ind Ltd 食品用酸化防止剤，アスコルビン酸誘導体およびその製造法
ZA852614B (en) * 1985-05-17 1986-10-09 Takeda Chemical Industries, Ltd. Ascorbic acid ethers and their production
ES8703865A2 (es) * 1985-06-28 1987-03-16 Barisintex Sa Perfeccionamientos en la patente de invencion n.544661 por: procedimiento de preparazcion de ascorbatos antagonistas h2-receptores.

Also Published As

Publication number Publication date
EP0259707A3 (en) 1988-11-02
US4939274A (en) 1990-07-03
DE3775666D1 (de) 1992-02-13
CA1328109C (en) 1994-03-29
EP0259707B1 (de) 1992-01-02
JPS63152374A (ja) 1988-06-24
JP2515556B2 (ja) 1996-07-10
EP0259707A2 (de) 1988-03-16

Similar Documents

Publication Publication Date Title
EP0262399A3 (en) Cyclic enol derivatives, production and use thereof
ATE121939T1 (de) Ascorbinsäure-tocopheryl-phosphatdiester zur hemmung der maillard-reaktion.
MY110226A (en) Therapeutic heterocyclic compounds.
KR900700494A (ko) 마크로시클릭 화합물
ES486349A1 (es) Procedimiento para la preparacion de 5-(2-imidazolin-2-il)- aminopirimidinas
ES2057126T3 (es) Metodo de tratamiento de la caquexia y algunos nuevos compuestos para utilizar en este metodo.
ES547826A0 (es) Un procedimiento para preparar nuevos derivados de 6-(4-fenilo sustituido -3(2h) piradazinona.
DE69030616D1 (de) Pharmazeutische Zusammensetzungen zur Hemmung der Maillardreaktion
IE872588L (en) Compounds
ATE71092T1 (de) Hydroxybutenolid-derivate, ihre herstellung und ihre verwendung.
HUT58695A (en) Process for producing substituted semicarbazone derivatives and artropodicide compositions containing them as active components
DE68917772D1 (de) 2-Alkyl-3-benzoylbenzofurane und diese enthaltende pharmazeutische Zusammensetzungen.
EP0270046A3 (en) Pharmaceutical composition for treatment of cataract
DE3752272D1 (de) Verwendung eines Thioesters zur Herstellung von pharmazeutischen Zusammensetzungen zur Behandlung von Ischämie und von Reperfusion-Syndromen
HUT41025A (en) Process for preparing octahydro-indolizine derivatives and pharmaceutical compositions containing such compounds as active ingredients
HUT45250A (en) Process for producing 5-substituted octahydro-indolysin derivatives and pharmaceutical compositions containing them as active components
EP0413278A3 (en) Use of xanthine derivatives against peptic ulcers
ATE81466T1 (de) Verwendung von 2-oxo-imidazolidin-derivaten zur prophylaxe und zur behandlung von herzinsuffizienz.
ZA885358B (en) Uricosuric composition
ATE81465T1 (de) Verwendung von 2-oxo-imidazolidin-derivaten zur behandlung von nierenkrankheiten.
NO167382C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 4-hydroxy-4-(substituerte alkenyl)cyklohexancarboxylsyrer.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties